Trientine

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Hypertrophic Cardiomyopathy

Drug Information

Target Indication

Hypertrophic Cardiomyopathy

Clinical Trial

Last updated: 8/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA9/5/2017

Cuprior

Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy.

Drug Science

Mechanism of action & safety profile

Developer

ONT.L

Oxford Nanopore Technologies plc

Related Pipeline

Pneumonia

Knee Osteoarthritis

Influenza

Chronic Lung Disease

Severe Acute Malnutrition

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts